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1. Introduction
Despite great efforts in developing novel screening, diagnosis and therapeutic strategies, the
incidence and mortality of ovarian cancer have not significantly changed in the last 30 years.
[1] It remains the leading cause of death from gynecologic malignancy with a lifetime proba‐
bility of developing the disease of 1 in 59.[1] Worldwide, approximately 200.000 women are
annually diagnosed with ovarian cancer,[2] and almost 70% of them will be diagnosed at ad‐
vanced stage disease.[3] With current treatment modalities, the 5-year survival rate ranges
from 80–95% for those with organ-confined or early stage disease (International Federation of
Gynecology and Obstetrics (FIGO) stage I-II); to 30 – 40% for those women with advanced dis‐
ease, FIGO stage III-IV. Thus, ovarian cancer is a challenging and complex malignancy.[4]
Surgical management of ovarian cancer remains as the cornerstone treatment of this disease.
[5] An adequate full surgical staging in women with early stage disease has demonstrated to
improve oncologic outcome.[6] On the other hand, complete surgical cytoreduction is the
only modifiable prognosis factor for patients with advanced disease. This chapter will de‐
scribe the rationale and surgical steps for an adequate surgical staging for women with early
stage ovarian cancer, and for obtaining the maximal surgical cytoreduction in women affect‐
ed by advanced stage and relapsed disease.
2. Surgical treatment of early stage epithelial ovarian cancer
Approximately 25% of newly diagnosed ovarian cancer will be early stage disease. Progno‐
sis is good with survival rates ranging from 80 % to 95 % when recommended treatment is
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followed.[5] These patients are initially managed by comprehensive surgical staging, which
is relevant not only for identifying women with truly early stage disease, but also to select
patients who will be candidates for adjuvant chemotherapy.
3. Rationale for surgical staging
Adequate surgical staging procedures include: exploration of abdomen/pelvis, peritoneal
washings, bilateral salpingo-oophorectomy, hysterectomy, peritoneal biopsies of Cul-de-sac,
pelvic walls, paracolic gutters, diaphragm, suspicious areas, omentectomy, appendectomy,
as well as pelvic and para-aortic node dissection up to the renal veins. (TABLE 1)[7],[8]
These procedures are needed to find hidden disease in nearly 18% of women[8], which has
implications in the prognosis and subsequent patient treatment.[9] Surgeon expertise is cru‐
cial given that it was correlated with under-staged ovarian cancer. Several studies demon‐
strated that over 30% of patients operated by general gynecologists or general surgeons
were upstaged by gynecologist oncologists by finding disease on pelvic-aortic lymph nodes,
diaphragm biopsies and omentum.[6, 10] Moreover, as it has been demonstrated, inade‐
quate initial surgical staging leads to a higher risk of developing recurrent disease despite
receiving adjuvant chemotherapy.[6] Thus, if the operative risk is not too high, all patients
should be routinely re-staged before starting chemotherapy.
• Peritoneal cytology/ascites drainage
• Careful and systematic abdominal exploration – inspect and palpate all peritoneal surface
• Infracolicomentectomy
• Total abdominal hysterectomy and bilateral salpingo-oophorectomy
• Pelvic and aortic lymphadenectomy
• Random and directed peritoneal biopsies – posterior cul-de-sac, bladder reflection, both pelvic sidewalls and both
paracolic spaces
• Biopsy or scrapings from the undersurface of both diaphragms
• Appendectomy (for mucinous histology)
Table 1. Surgical staging procedures for early stage ovarian cancer
4. Surgical staging procedures
Midline vertical incision is the recommended surgical approach for initial management of
suspected early stage ovarian cancer. The incision is firstly made from the pubis to the um‐
bilicus and then progressed to xifoid appendix, if surgical staging is indicated following the
frozen section diagnosis. The abdominal-pelvic cavity is opened and visualized. If free fluid
is present, a minimum sample of 100 cc[3] should be obtained for cytological examination.
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Peritoneal washing from paracolic gutters, pelvis and abdominal cavity should be done in
the absence of ascites. It is estimated that over 30% of patients with stage I disease have tu‐
moral cells on cytological examination.[11] Careful inspection and palpation is preformed to
detect extra-ovarian implants in a systematic way: starting by right paracolic space, advanc‐
ing the hand to the right kidney, suprahepatic space, the right diaphragm, right hepatic
lobe, gallbladder, Morrison´s pouch, left hemi-diaphragm, left hepatic lobe, spleen, stomach,
transverse colon, left kidney and left paracolic space. The lesser sac is entered on the left side
of the gastrocolic ligament. Both surfaces of the mesentery should be examined and retro‐
peritoneal vascular areas should be palpated as well. The result of this comprehensive pro‐
cedure should be properly described.
The ovaries need to be examined for capsule rupture or external excrescences. The affected
ovary must then be removed for frozen section. Although the influence on the prognosis of
the intraoperative rupture of malignant ovarian tumors is controversial,[12] adnexal masses
should be removed intact. If malignancy is confirmed in the frozen section, full surgical
staging, as previously described, must be performed by the extension of the incision up to
xifoid appendix. Contralateral oophorectomy and total hysterectomy is completed due to
the possibility of synchronous cancer.
Even though controversial, random peritoneal biopsies are indicated in early-stage disease.
A retrospective study demonstrated that less than 4% of patients with ovarian cancer were
upstaged due to positive peritoneal biopsies. No patient, however, had a change in treat‐
ment recommendations based on these biopsies.[13] Infracolic omentectomy should be per‐
formed from the hepatic to splenic flexure. During dissection, the lesser sac is developed
dissecting the posterior and anterior layer of the transverse mesocolon, while preserving the
middle colic artery. The omentum is removed and the pedicles are sequentially sutured –
ligated. Appendectomy is only reserved for mucinous histology.
5. Retropetitoneal lymph node dissection
The incidence of lymph-node involvement in patients with disease confined to the ovary is
5% in only pelvic nodes, 9% in aortic nodes and 6% in both pelvic and aortic nodes.[14] Sys‐
tematic lymphadenectomy as part of surgical staging of apparent early stage ovarian cancer
is associated with a statistically significant increase in median operative time, median blood
loss, and the proportion of patients undergoing blood transfusions.[15] Systematic lympha‐
denectomy, however, significantly improves progression-free survival (PFS) rates, without a
statistically significant impact on overall survival (OS). [14, 15] Lymphatic drainage of the
ovaries is known to follow the gonadal blood supply that reaches the renal vein, on the left
side, and the inferior vena cava, on the right side. Pelvic lymphadenectomy should include
removal of nodes from paravesical and pararectal spaces, including bilateral common iliac
nodes. Aortic nodes should be removed from aortic bifurcation to the renal veins.[14]
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6. Minimally invasive surgery for surgical staging ovarian cancer
Over the last years, laparoscopy has gained an important role for the management of suspect‐
ed adnexal masses. High-volume centers have reported their experience in performing a com‐
prehensive surgical staging by using minimally invasive surgery.[16],[17] Nezhat et al. [16]
reported a case series of 36 patients with early stage invasive ovarian carcinoma managed by
laparoscopy. They showed 100% OS rate with a mean duration of follow-up of 55.9 months.
Chi et al. [17] conducted a case control study by staging 20 patients with early ovarian cancer
with laparoscopy compared with 30 patients staged with laparotomy. There were no differen‐
ces in the omental specimen size or number of lymph nodes removed. Blood loss and hospital
stay were lower for the laparoscopy group, with longer operating time. There were no conver‐
sions to laparotomy or other intraoperative complications in the laparoscopy group.
Despite laparoscopic staging of early ovarian cancer seems to be a safe and feasible proce‐
dure performed by expert surgeons, the possibility of cyst rupture or port-site metastases re‐
main controversial. The immediate effect of tumor rupture is that a patient with a
potentially curable disease will require additional adjuvant chemotherapy. Preoperative
evaluation is essential, as well as the surgical experience and the quality of laparoscopic in‐
struments.[18] Even though there are no specific recommendations, adnexal masses up to
5-6 cm could be reasonably managed by laparoscopy.
The etiology of port-site metastases is uncertain. Several hypotheses include tumor cell en‐
trapment, direct spread from the trocar in which instruments are exchanged, and the ‘‘chim‐
ney effect,’’ which suggests that tumor cells travel along the sheath of the trocars with the
leaking gas. Port-site metastases have been reported in 1% to 2% of patients with ovarian
cancer. However, <5% of port metastases are clinically detected and these sites are likely to
respond to chemotherapy.[9]
Robotic surgery has emerged as an innovative minimally invasive approach in the field of
gynecology. The da Vinci Surgical System (Intuitive Surgical, Inc, Sunnyvale, California,
USA) offers several advantages over conventional laparoscopy including three-dimensional
view, greater dexterity, and tremor filtration. Most of the data regarding the application of
robotic technology for ovarian cancer staging are included in the literature used in the as‐
sessment for its implementation in other gynecologic malignancies, such as cervical and en‐
dometrial cancer.[19] Data are still scarce but promising.
7. Treatment of advanced stage disease: Surgical cytoreduction
Advanced-stage disease means that the disease is extended to pelvic/ aortic lymph nodes,
peritoneum, intra-abdominal organs or disease outside the abdominal cavity.[20] In 1975, a
landmark study quantified residual disease and demonstrated for the first time an inverse
relationship between residual tumor and oncologic outcome. [21] The goal of surgery is to
resect as much tumor as possible obtaining, ideally, a complete resection. The standard
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worldwide recommendation consists of primary maximal surgical cytoreduction followed
by 6 cycles of intravenous carboplatin plus paclitaxel. [5,7] An alternative strategy is re‐
served for selected patients and it includes surgical cytoreduction in between chemotherapy
courses, usually after three or four cycles. This strategy is called neoadjuvant chemotherapy
followed by interval debulking surgery. (fig 1) The appropriate selection of patients for each
modality of treatment will be described below.
Figure 1. Treatment options for advanced stage ovarian cancer
8. Prognostic factors
Prognostic factors in women with advanced stage EOC was described in literature based on
retrospective data.[22] Recently, Du Buois et al., [23] did a combined exploratory analysis of
three prospective randomized phase III multicenter trials, which enrolled 3388 patients with
advanced EOC between 1995 and 2002. Univariate and multivariate analysis revealed non-
modifiable significant prognostic factors for OS and PFS such as: age, performance status
(ECOG 2 versus 0-1), FIGO stage (IIIC-IV versus IIB-IIIB), subtype histology (Mucinous ver‐
sus serous), histology grade (grade 2-3 versus 1), presence of large volume ascites (> 500
mL). The only significant modifiable prognosis factor was postoperative residual tumor (0
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versus >1 mm). (Table 2) This study highlighted the importance of an adequate surgical
management of women affected by ovarian cancer as the key-point for improving oncologic
outcomes given that the quality of surgical cytoreduction was the only modifiable prognosis
factor for survival.
Non-modifiable
• Patient performance status
• FIGO stage
• Hystology subtype
• Hystology grade
• Large volume of ascites
Modifiable
• Post-surgical residual tumor
Table 2. Prognosis factors of overall survival and progression free survival in patients with advanced stage epithelial
ovarian cancer
9. Rationale for primary surgical cytoreduction
1. Improvement of oncologic outcomes: a large body of retrospective and non-random‐
ized prospective studies consistently show an inverse correlation between survival and
the amount of postoperative residual disease [22]. Results of two meta-analysis[22],[24]
evaluated women affected by advanced stage EOC that were treated with primary sur‐
gical cytoreduction and platinum-based neoadjuvant chemotherapy and demonstrated
a mean weighted median survival of 29 and 24 months respectively.
2. Surgical reduction of tumor burden prior to chemotherapy: it has been postulated that
the proportion of tumor cells destroyed with each cycle of chemotherapy is constant.
Thus, in cases of tumor cells not resistant to chemotherapy, fewer cycles would be nec‐
essary to eradicate them if the absolute number were less.[25] In addition, tumor size is
correlated with an increased spontaneous mutation rate of malignant cells.[26] Animal
models have also demonstrated that drug exposure allows the resistant cells to outgrow
the sensitive tumor cells population.[27] Primary surgical cytoreduction, thus, reduces
the number of cancer cells decreasing the chance of inducing drug resistance.
3. Improved drug diffusion: large bulky tumors may have hypoperfused areas where
concentration of chemotherapy agents can be suboptimal, increasing the possibility of
drug resistance.[28]
4. Increased tumor cells growth rate: During initial tumor growth, cancer cell division is
almost exponential. But then, cell growth reaches a plateau. Thus, the great majority of
cells in large tumoral masses are not dividing, being in G0 phase of the cell cycle, which
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are essentially resistant to chemotherapy.[29] Primary surgical cytoreduction may stim‐
ulate G0 residual tumor cells to re-enter in the normal cell cycle, increasing the chemo‐
therapy efficacy.[29]
10. Residual tumor disease: Definition and relevance
Residual tumor disease is commonly described as the diameter, in millimeters, of the biggest
nodule left after surgical debulking. Griffiths et al., first described the importance of residual
disease after surgery in women with ovarian cancer.[21] They demonstrated an inverse rela‐
tionship between residual disease and patient survival. In 1994, the Gynecology Oncology
Group (GOG) published a sub-analysis of two retrospective series (GOG protocol 52 & 97)
of patients affected by advanced stage EOC who underwent primary cytoreduction fol‐
lowed by chemotherapy. The study showed significant differences in OS in women with mi‐
croscopic disease or less than 2 cm in comparison with of residual disease of more than 2 cm
diameter. The maximum diameter of residual disease was firstly found to be an independ‐
ent predictor of OS after controlling other variables. Thus, surgery with residual disease of
less than 2 cm was defined as “optimal” cytoreduction; while more than 2 cm was called
“suboptimal”.[30]
In 2002, a meta-analysis of 6885 patients with stage III or IV ovarian cancer was reported.
[22]The study analyzed 81 cohorts of patients treated in the platinum era to evaluate the ef‐
fect of maximal cytoreductive surgery and other prognostic factors on survival. The investi‐
gators demonstrated that each 10% increase in the proportion of patients undergoing
maximal cytoreduction was associated with a concomitant 5.5% increase in median cohort
survival time. The mean weighted median survival time was 29 months. Thus, for all clinical
trials that followed, the GOG established ≤ 1 cm residual disease as the criterion for optimal
cytoreduction.
Winter III et al. [31] reported the GOG collective experience analyzing the data of seven tri‐
als (GOG 11, 114, 132, 152, 158, 162 and 172) that studied the efficacy of chemotherapy in
1895 stage III and 360 stage IV ovarian cancer patients. All patients underwent primary de‐
bulking surgery followed by 6 courses of cisplatin and paclitaxel. Residual disease after sur‐
gery was an independent prognostic factor. The median OS reported was 79.1, 42.4 and 35
months in patients with microscopic, 1-10 mm and > 10 mm of residual disease, respectively.
The authors suggested a modification of the term “optimal residual disease” from < 1 cm to
microscopic.
These results were confirmed when 3 large phase III randomized trials conducted by the AGO
(AGO-OVAR 3, 5 and 7) of patients with stage IIB-IV ovarian cancer receiving platinum/
taxanes chemotherapy following primary cytoreduction surgery were analyzed. [23] Patients
with microscopic residual disease had significantly longer median OS than those with any re‐
sidual disease, 99.1 months versus less than 36 months, respectively. Thus the current goal of
the surgery in ovarian cancer is to obtain a complete cytoreduction. (Fig 2)
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 The goal of the surgery in ovarian cancer 
is to obtain a complete cytoreduction  
Figure 2. Goal of the surgery in ovarian cancer
Chang and Bristow in 2012, reported a single institution series and cooperative group trials
since 2003 of patients who underwent primary debulking surgery followed by adjuvant che‐
motherapy. Over 14000 patients in 15 studies were analyzed.[32] A marked inverse correla‐
tion between the maximal diameter of residual tumor and OS was noted. The weighted
median OS for 3593 patients with no gross residual disease was 77.8 months compared to
39.0 months for the 4780 patients with 0.1–1 cm residual disease and 31.1 months for the
3518 patients with residual tumor >1 cm in maximal diameter. The magnitude of the incre‐
mental improvement in OS strongly suggests that complete resection should be the surgical
objective whenever feasible.
11. Feasibility of complete primary cytoreduction
In the presence of a preoperative suspected adnexal mass whit ascites and peritoneal carci‐
nomatosis are present, the feasibility of complete cytoreduction should be determined by ex‐
clusion of multiple liver or pulmonary metastases by imaging studies such as computed
tomography (CT). In the absence of extra-peritoneal lesions and surgical contraindications,
patients should undergo primary debulking surgery. The feasibility of optimal cytoreduc‐
tion depends on the disease distribution, the patient´s overall medical condition and the sur‐
geon’s expertise. However, obtaining an optimal cytoreduction ≤ 1 cm of residual disease is
not an easy task. In highly specialized centers, the rate with optimal primary cytoreduction
is over 75 %. (Fig 3) But this rate falls down to 25% when low-volume ovarian cancer surger‐
ies centers are included in the analysis. (Fig 4) Nevertheless, as it was previously mentioned,
according with collecting data of the latter,[23],[31] primary debulking surgery is beneficial
if complete cytoreduction is achieved. According with the literature, this is achievable in on‐
ly 30% of patients when a gynecologist oncologist performs the surgery, a higher rate when
compared with general gynecologists or general surgeons.[33]-[38]
12. Neoadjuvant chemotherapy followed by interval debulking surgery
Despite upfront primary debulking surgery (PDS) for newly diagnosed patients with ad‐
vanced stage ovarian cancer is considered the standard of care,[5] limitations to this strategy
have been postulated.[39],[40] For instance, patients with incomplete primary cytoreduction
seem to have no meaningful impact on OS.[23],[31] Furthermore, only experienced surgeons
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Figure 3. Stratified residual tumor on expert series/international traits
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Figure 4. Stratified residual tumor on less experienced centers
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with extended formal training in cytoreductive techniques obtain an acceptable complete
primary cytoreduction rate.[41]-[43]
Consequently, an alternative approach such as neoadjuvant chemotherapy (NACT) has
been proposed by several authors.[39],[40] This strategy of treatment consists in the admin‐
istration of at least 3 courses of platinum-taxanes chemotherapy followed by an interval de‐
bulking surgery (IDS) and further adjuvant treatment in patients responsive to
chemotherapy. [44] (Figure 1) The goal of this modality is to reduce the extension of the dis‐
ease and, by performing a less radical surgical procedure, to improve the complete cytore‐
duction rate reducing the surgical time and complication rate, while improving the PFS and
OS rate.
Objective indications for neoadjuvant chemotherapy are patients with poor performance
status and with significant medical co-morbidities making them unsuitable for an aggressive
debulking surgery. These indications include, however, the smallest proportion of patients
who underwent neoadjuvant chemotherapy in the series published in the literature. [39],
[40],[45],[46] The majority of women receive either NACT or PDS based on tumor extension
and on estimated tumor resectability.[47] The latter is a subjective and highly surgeon-de‐
pendent indication. [24] Although several criteria have been tested for predicting the surgi‐
cal resectability of ovarian tumors, its accuracy and clinical applicability is still controversial.
[48] Some of these criteria include ascites volume, serum CA 125 values[48] and computer
tomography scan parameters.[49] For example, terms like “dense adhesion between bowel
and omentum”, “large diaphragm disease”, and “large tumor nodules adherent to abdomi‐
nal structures” have been postulated by some authors as criteria of unresectability.[50]
These terms show how subjective is the definition of a patient as debulkable or not. These
criteria are mostly based on CT scan findings but, sometimes, a direct laparoscopic assess‐
ment of is recommended.[51] (Fig. 5)
On the other hand it is a common belief to associate NACT with less complex surgical proce‐
dures, shorter surgical time, and lower incidence of complications after IDS.[44],[46] How‐
ever, this strategy does not exclude the necessity of performing complex surgical procedures
at the time of IDS in order to obtain an optimal cytoreduction. Thus, referring these patients
to a specialized gynecologist is mandatory as well.
Recently, the results of a randomized, controlled, prospective trial conducted by the Europe‐
an Organization for Research and Treatment of Cancer (EORTC) were published.[52] Six
hundred and seventy patients with stage IIIC and IV ovarian cancer were randomly as‐
signed to primary cytoreductive surgery group or neoadjuvant chemotherapy group. There
were no significant differences in OS (29 months for primary cytoreductive surgery group
versus 30 months for neoadjuvant chemotherapy group) between the two groups. Complete
cytoreduction with no gross residual disease was possible in 20% of patients who under‐
went primary cytoreduction and 52% of those who had neoadjuvant chemotherapy. On
multivariate analysis, the strongest independent predictor factor of prolonged survival was
the absence of residual tumor after surgery (p < 0.001). The authors concluded that neoadju‐
vant chemotherapy followed by interval debulking surgery has similar efficacy compared
with primary debulking surgery followed by chemotherapy for patients with stage IIIC or
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IV ovarian cancer and complete resection of all gross lesions remains the objective of the cy‐
toreductive surgery whether performed as primary or after neoadjuvant chemotherapy.
However, optimal cytoreduction (<1 cm residual disease) was achieved in only 41.6% of pa‐
tients in the PDS arm, a substantially lower rate than the published by expert series.[31],[42],
[43] The PFS and OS for patients randomized to the PDS arm were substantially lower than
those reported in previous studies, including prospective trials of the Gynecologic Oncology
Group (GOG) as well.[30],[31],[43]
A recent report from the Memorial Sloan-Kettering Cancer Center contradicts the findings of
the EORTC study and suggests that the strategy of neoadjuvant chemotherapy requires fur‐
ther investigation. A total of 316 stage IIIC–IV ovarian cancer patients were treated at the
institution during the same period in which the EORTC-NCIC trial were evaluated, using
identical inclusion criteria.[53] The optimal cytoreduction rate was 71% and the median OS
time was 50 months. This study suggested that primary cytoreductive surgery should be
considered as t he preferred initial management strategy for patients with this disease.
It seems, therefore, that neoadjuvant chemotherapy should not be performed routinely in
patients with advanced ovarian cancer and be done in selected patients who are at risk of
morbidity associated with primary surgery and less likely to have a complete cytoreduction.
(Fig. 5)
Figure 5. Initial approach of suspected advanced ovarian cáncer
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13. Surgical cytoreduction technique
Women should be placed on supine position with legs spread apart. Vertical midline inci‐
sion is recommended in order to access to the entire abdominal cavity. Ascites is evacuated
and sent for cytological evaluation. As described above, a careful inspection and palpation
of the entire peritoneal cavity and retroperitoneum is carried out in order to assess the ex‐
tent of the primary and metastatic disease. The localization and diameter of the primary tu‐
mor and its extension into surrounding organs is described as the diameter of the larger
metastases. Sometimes, there are regions that cannot be accessed before larger tumor masses
are removed. This careful inspection and palpation is essential in order to establish the feasi‐
bility and extension of surgical cytoreduction. Complete cytoreduction may by difficult in
cases of bulky suprarenal nodes, extensive disease in the liver parenchyma, along the root of
the small bowel mesentery and in the bowel serosa, close to the origin of the superior mes‐
enteric artery, or in the porta hepatis. If complete surgical cytoreduction is not feasible, neo‐
adjuvant chemotherapy is preferred. (Figure 5)
Radical omentectomy use to be the first surgical step because it is the first tumor encoun‐
tered upon entering the peritoneal cavity. The infracolic omentum is separated from the
transverse colon and resected. If the omental metastases involve the gastrocolic omentum, it
is resected as well. The next step is to remove the primary tumor in the pelvis with the other
adnexa and the uterus in the usual fashion if no extension to other pelvic organs is present.
However, advanced ovarian cancer often involves the uterus, rectosigmoid, cecum, ileum
and bladder. Metastases of the pelvic peritoneum sometimes completely obliterate the ante‐
rior and posterior cul-de-sac. In this case, the retroperitoneal approach is the most reasona‐
ble way for removing in block the entire tumor. This procedure is accompanied by
performing a rectosigmoid resection with an end-to end mechanical anastomosis.[54] Tumor
spread to the hilum of the spleen may be carefully inspected as well. Splenectomy may be
sometimes indicated to achieve maximal tumor debulking. Any peritoneal implants should
be removed, particularly if there are large, isolated masses and their removal will render the
patient optimally cytoreduced. Diaphragm peritoneum should be visualized and resected if
the disease is present. Sometimes, it can involve muscle resection that can be sutured with
non-reabsorbed monofilament continuous suture. Pelvic and /or aortic lymph node involve‐
ment is seen is approximately 60% of patient with advanced stage disease. Despite contro‐
versial, pelvic and aortic lymphadenectomy should be completed starting form aortic
bifurcation up to the renal veins. The incidence of complications and morbidity of this ap‐
proach should be also taken into consideration for patient selection. The most common com‐
plications include: infections, cardiac morbidity, pulmonary thromboembolism,
coagulopathy, gastrointestinal, renal failure, re-laparotomy and death.
14. Surgical treatment of relapsed ovarian cancer: Secondary
cytoreduction
Once recurrence is confirmed, the next step is to determine the best treatment approach for
each individual case. Recurrent epithelial ovarian carcinoma is, however, a therapeutic di‐
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lemma for physicians. To date, there is no consensus for optimal treatment strategies. Three
essential options are proposed: surgical resection followed by chemotherapy, chemotherapy
only or enrollment into clinical trials. This dilemma will be fundamentally responded by the
localization of the disease, by the disease free interval (DFI) between the end of standard
front-line chemotherapy (platinum/taxanes-based) and the date of documented disease re‐
currence. This period will divide patients in three groups: platinum sensible with a DFI more
than 6 months; platinum resistant: patients with a DFI less than 6 months; and the group of
platinum refractory: patients who will never respond to front line therapy or who will experi‐
ence progression of disease. The latter represents 20-30% of the patients with FIGO stage III-
IV who underwent surgical cytoreduction followed by carboplatin /paclitaxel.[55],[56] DFI
has been established as the most important predictor factor for response to treatment of the
relapsed disease.[55],[57],[58]
15. Secondary cytoreduction
Surgical resection for ovarian cancer recurrence means secondary cytoreduction. Although
primary cytoreductive surgery is well accepted as the cornerstone of initial management,
the use of cytoreductive surgery in the setting of recurrent disease is defined less clearly.
Benefits of secondary cytoreduction are encountered in several studies.[59] No randomized
studies exist regarding the benefits of surgical resection over chemotherapy in patients with
recurrent disease. The available data is controversial and biased by the decision whether or
not to expose patients to a surgical treatment. In general, studies included patients with
more favorable characteristics such as younger age, fewer medical comorbidity, scarce num‐
ber of lesions, better performance status, absence of ascites at recurrence, early stage at diag‐
nosis, DFI more than 12 months, and optimal primary cytoreduction.[60]-[64] All of the
previous characteristics are favorable prognostic factors and constitute the standard indica‐
tions for secondary surgical resection.[60] A recent meta-analysis studied 2.019 patients en‐
rolled in 40 retrospective and prospective trials who underwent secondary cytoreduction
due to recurrent ovarian cancer. The mean weighted median OS time after recurrence was
30.3 months. Complete cytoreduction was identified as an independent factor for the im‐
proving OS after secondary cytoreduction. In addition, the multivariate analysis showed
that the survival time is increased 3.0 months each 10 % increase in the proportion of pa‐
tients undergoing complete cytoreductive surgery.[65]
The objective of secondary cytoreduction should be to achieve complete debulking. In pa‐
tients who are able to tolerate a major surgical procedure, secondary cytoreduction should
be offered to those with a single site disease regardless of DFI, as well as to all patients with
a DFI of greater than 30 months regardless the amount of disease sites. Patients with carci‐
nomatosis and a DFI of less than 12 months should not be considered for secondary cytore‐
duction. The decisions must be, however, individualized based on each patient’s goals,
performance status, operative risk, and available therapeutic options.[66] (Table 3)
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Disease-Free Interval Single site ofrecurrence
Multiple site od recurrence – but no
carcinomatosis Carcinomatosis
6 – 12 months Offer SC Consider SC No SC
12 – 30 months Offer SC Offer SC Consider SC
> 30 months Offer SC Offer SC Offer SC
Table 3. Recommendations for secondary cytoreduction (SC)
16. Specialized gynecologists
Surgical evaluation of a pelvic mass is one of the most common indications for gynecologic
surgery and, therefore, it is unlikely that all patients with adnexal masses will be referred to
a gynecologic oncologist. To assist in the referral process, the Society of Gynecologic Oncolo‐
gy established a guideline for patient referral with suspected ovarian cancer.[67]
It has been demonstrated that patients operated on by gynecologic oncologists are more
likely to undergo an adequate staging procedure in early stage disease[34],[36],[37],[68] and
a better percentage of optimal primary cytoreduction in advanced stage disease can be ach‐
ieved in comparison to general gynecologists or general surgeons.[33]-[38] Moreover, many
studies from several countries around the world have shown over 10 months increased OS
when ovarian cancer patients were initially operated by a gynecological oncologist rather
than general gynecologist [33],[34],[69]-[71] or general surgeons.[68],[72] Thus, optimal pri‐
mary cytoreductive surgery performed by a surgeon with extended formal training in cytor‐
eductive techniques followed by an appropriate chemotherapy combination is among the
most powerful clinician-driven determinants of survival for women with ovarian cancer.[24]
17. Multidisciplinary team and centralization of treatment
Ovarian cancer is a challenging, complex and multidisciplinary disease. It is not only impor‐
tant how well trained physicians are, but also how many physicians of different specialties
are involved in the management of this malignancy. The holistic conception of patient care
and the intrinsic complexity of ovarian cancer require the involvement of different special‐
ties to optimize the quality of care. The concept of multidisciplinary team approach in ovari‐
an cancer is not restricted to the operating room settings. Multidisciplinary approach is
crucial from the diagnosis to the demise of disease.
Results of different studies consistently show that patients with ovarian cancer treated at re‐
ferral teaching high-volume hospitals receive better quality of care as accomplished by bet‐
ter surgical staging, better optimal cytoreduction[35],[39],[69],[73]-[75] and better
chemotherapy administration rate and schemes.[69],[75]-[78] Treating patients at referral
hospitals was independently associated with 10%-20% increased probability of survival at 5
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years after first treatment.[69],[72],[73],[75],[79] In absolute numbers, this translates in an ex‐
tension of survival of more than 10 months.[79]
Despite the consensus and the advantages explained above, population-based studies indi‐
cate that access to specialist care in gynecologic oncology for women with suspected ovarian
cancer has been less than universal.[35],[36],[70] Reports from countries such as USA,[80]
and UK[35],[81] have consistently shown that the majority of patients were treated in low-
volume hospitals by low-volume surgeons. For example, the accessibility of patients with
ovarian cancer to a specialized center was reported in 18% of patients in The Nether‐
lands[74], 35% in Canada[72] and 40% in Maryland, USA.[82]
In summary, the configuration of health-care delivery systems to facilitate quick and consis‐
tent centralized referral will be necessary to ensure widespread access for women with sus‐
pected ovarian cancer to such health-care providers. Only through such efforts will
contemporary patterns of surgical practice conform to the definition of high-quality cancer
care.[83]
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